Abstract 1581P
Background
Surgery with perioperative chemotherapy has been standard of care in patients with locally advanced gastric and gastroesophageal junction (GEJ) cancer since FLOT4-AIO trial. However, less than half of patients complete all adjuvant cycles. We studied total neoadjuvant chemotherapy with FOLFIRINOX regimen followed by surgery in this setting.
Methods
We conducted non-randomized, open-label, single-center phase II study in 119 patients with locally advanced resectable gastric and GEJ cancer. Sixty patients were enrolled to received 8 cycles of FOLFIRINOX preoperatively. This prospective cohort was compared to the retrospective cohort (n = 59), that received standard perioperative FLOT regimen (4 cycles before and 4 cycles after surgery). The primary endpoint was disease-free survival (DFS). Secondary endpoints were safety profile and pathological complete response rate (pCR).
Results
In the FOLFIRINOX and FLOT groups 78,6% and 77,8% of patients completed all planned cycles and underwent surgery, respectively. Dose reductions and drug withdrawal rates were higher in the FLOT group. More patients achieved pCR and near-pCR in the FLOT group by three different tumor regression grading systems (TRG 1a/b by Becker, 1/2 by Mandart, and 3/4 by Lavnikova): 47,7%, 40,5%, and 35,7% in the FLOT group and 25%, 27,3%, and 29,6% in the FOLFIRINOX group, respectively, though statistically insignificant. pCR or partial pathological response by any of TRG systems did not predict one-year DFS regardless of the treatment regimen. One-year DFS was numerically higher in the FOLFIRINOX group - 90,4% vs 67,5 % in the FLOT group (hazard ratio [HR] 0,65, 95% CI 0,29 – 1,45, p=0,29). The risk of recurrence in the FOLFIRINOX group was lower than in the FLOT group (odds ratio [OR] 0,40, 95% CI 0,16-0,97, p=0,047). Regional lymph node involvement (ypN2), lymphatic, vascular and perineural invasion negatively affected DFS (p=0,046; p=0,014; p=0,0021; p=0,04, respectively).
Conclusions
The total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with locally advanced gastric and GEJ cancer demonstrated comparable to the perioperative FLOT one-year DFS rate regardless of pCR and manageable safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22
1644P - The mutation landscape and evolution pattern of liver or peritoneal metastasis in pancreatic cancer
Presenter: Guoliang Yao
Session: Poster session 22